NASDAQ Framework: Exact Sciences Corporation
1: Exact Sciences schedules second quarter 2024 earnings call MADISON, Wis., July 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 16 days ago Exact Sciences to Participate in June Investor Conferences MADISON, Wis., May 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Business Wire • last month Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® MADISON, Wis., May 24, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test Business Wire • last month Exact Sciences Earns 2024 Great Place To Work® Certification™ MADISON, Wis., May 22, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company’s work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To Wor Business Wire • 2 months ago Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising. Business Wire • 2 months ago Exact Sciences Announces First-Quarter 2024 Results MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. Business Wire • 2 months ago Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024 MADISON, Wis., May 07, 2024--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024 Business Wire • 2 months ago Exact Sciences to Participate in May Investor Conference MADISON, Wis., May 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 2 months ago Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Business Wire • 3 months ago Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n Business Wire • 3 months ago Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 MADISON, Wis., April 08, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the mos Business Wire • 3 months ago Exact Sciences Schedules First Quarter 2024 Earnings Call MADISON, Wis., April 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 3 months ago Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment ROCHESTER, Minn. & MADISON, Wis., April 04, 2024--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients Business Wire • 3 months ago Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer MADISON, Wis., March 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing Business Wire • 3 months ago Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner MADISON, Wis., March 27, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world. Business Wire • 3 months ago The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study MADISON, Wis., March 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. Business Wire • 4 months ago Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer MADISON, Wis., March 07, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, gender Business Wire • 4 months ago Exact Sciences to Participate in March Investor Conference MADISON, Wis., February 26, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 4 months ago Exact Sciences Announces Fourth Quarter 2023 Results MADISON, Wis., February 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023. Business Wire • 4 months ago Exact Sciences Schedules Fourth Quarter 2023 Earnings Call MADISON, Wis., February 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 5 months ago View Source2: Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 3 months ago View Source3: Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. View Source
Exact Sciences Corporation, headquartered in Madison, Wisconsin, is a leading provider of cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test for colorectal cancer, and competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and chemotherapy benefit for breast and colon cancer. Additionally, Exact Sciences is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening 456.
4: Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 3 months ago View Source5: Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. View Source6: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. View Source
UNKNOWN
The provided facts do not specify whether Exact Sciences Corporation is still led by its founders or if the founders are heavily involved.
The provided facts do not specify whether Exact Sciences Corporation is still led by its founders or if the founders are heavily involved.
MEDIUM RISK
Exact Sciences Corporation has shown consistent revenue growth, with first-quarter 2024 revenue increasing by 6% year-over-year to $638 million 7. The company is also actively developing new products and expanding its market presence, as evidenced by its participation in multiple investor conferences and scientific meetings 8. However, the company's stock has experienced significant volatility, losing 52.04% of its value over the last 52 weeks 9. Additionally, there are concerns about competing blood-based tests and the company's aggressive push toward profitability in 2023, which it is now course-correcting 10. These factors suggest that while Exact Sciences is not in immediate financial distress, it faces challenges that could impact its financial stability in the medium term.
Exact Sciences Corporation has shown consistent revenue growth, with first-quarter 2024 revenue increasing by 6% year-over-year to $638 million 7. The company is also actively developing new products and expanding its market presence, as evidenced by its participation in multiple investor conferences and scientific meetings 8. However, the company's stock has experienced significant volatility, losing 52.04% of its value over the last 52 weeks 9. Additionally, there are concerns about competing blood-based tests and the company's aggressive push toward profitability in 2023, which it is now course-correcting 10. These factors suggest that while Exact Sciences is not in immediate financial distress, it faces challenges that could impact its financial stability in the medium term.
7: Exact Sciences schedules second quarter 2024 earnings call MADISON, Wis., July 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 16 days ago Exact Sciences to Participate in June Investor Conferences MADISON, Wis., May 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Business Wire • last month Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® MADISON, Wis., May 24, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test Business Wire • last month Exact Sciences Earns 2024 Great Place To Work® Certification™ MADISON, Wis., May 22, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company’s work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To Wor Business Wire • 2 months ago Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising. Business Wire • 2 months ago Exact Sciences Announces First-Quarter 2024 Results MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. Business Wire • 2 months ago Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024 MADISON, Wis., May 07, 2024--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024 Business Wire • 2 months ago Exact Sciences to Participate in May Investor Conference MADISON, Wis., May 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 2 months ago Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Business Wire • 3 months ago Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n Business Wire • 3 months ago Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 MADISON, Wis., April 08, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the mos Business Wire • 3 months ago Exact Sciences Schedules First Quarter 2024 Earnings Call MADISON, Wis., April 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 3 months ago Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment ROCHESTER, Minn. & MADISON, Wis., April 04, 2024--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients Business Wire • 3 months ago Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer MADISON, Wis., March 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing Business Wire • 3 months ago Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner MADISON, Wis., March 27, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world. Business Wire • 3 months ago The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study MADISON, Wis., March 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. Business Wire • 4 months ago Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer MADISON, Wis., March 07, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, gender Business Wire • 4 months ago Exact Sciences to Participate in March Investor Conference MADISON, Wis., February 26, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 4 months ago Exact Sciences Announces Fourth Quarter 2023 Results MADISON, Wis., February 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023. Business Wire • 4 months ago Exact Sciences Schedules Fourth Quarter 2023 Earnings Call MADISON, Wis., February 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 5 months ago View Source8: Exact Sciences schedules second quarter 2024 earnings call MADISON, Wis., July 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 16 days ago Exact Sciences to Participate in June Investor Conferences MADISON, Wis., May 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Business Wire • last month Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO® MADISON, Wis., May 24, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test Business Wire • last month Exact Sciences Earns 2024 Great Place To Work® Certification™ MADISON, Wis., May 22, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company’s work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To Wor Business Wire • 2 months ago Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising. Business Wire • 2 months ago Exact Sciences Announces First-Quarter 2024 Results MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. Business Wire • 2 months ago Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024 MADISON, Wis., May 07, 2024--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024 Business Wire • 2 months ago Exact Sciences to Participate in May Investor Conference MADISON, Wis., May 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 2 months ago Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Business Wire • 3 months ago Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n Business Wire • 3 months ago Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 MADISON, Wis., April 08, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the mos Business Wire • 3 months ago Exact Sciences Schedules First Quarter 2024 Earnings Call MADISON, Wis., April 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 3 months ago Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment ROCHESTER, Minn. & MADISON, Wis., April 04, 2024--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients Business Wire • 3 months ago Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer MADISON, Wis., March 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing Business Wire • 3 months ago Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner MADISON, Wis., March 27, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world. Business Wire • 3 months ago The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study MADISON, Wis., March 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. Business Wire • 4 months ago Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer MADISON, Wis., March 07, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, gender Business Wire • 4 months ago Exact Sciences to Participate in March Investor Conference MADISON, Wis., February 26, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Business Wire • 4 months ago Exact Sciences Announces Fourth Quarter 2023 Results MADISON, Wis., February 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023. Business Wire • 4 months ago Exact Sciences Schedules Fourth Quarter 2023 Earnings Call MADISON, Wis., February 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Business Wire • 5 months ago View Source9: Artisan Mid Cap Fund highlighted stocks like Exact Sciences Corporation (NASDAQ:EXAS) in the second quarter 2024 investor letter. Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products. The one-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 12.24%, and its shares lost 52.04% of their value over the last 52 weeks. On July 15, 2024, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $47.05 per share with a market capitalization of $8.682 billion. View Source10: "Among our top detractors were Lattice Semiconductor, Exact Sciences Corporation (NASDAQ:EXAS) and Celsius. Exact Sciences is a leading provider of diagnostic testing and a maker of the noninvasive colorectal cancer screening test Cologuard®. Shares declined due to investor concerns around competing blood-based tests. Our view has been that blood tests, while potentially more convenient, have historically been unable to match the accuracy of stool testing (especially when it comes to detecting early cancers). In addition, the company may have pushed too aggressively toward profitability in 2023. It is now course-correcting by modestly expanding its sales force and tempering profit growth progress in 2024. At the current valuation, we believe the stock fails to capture Cologuard’s significant long-term growth and margin expansion opportunity as the public health need for materially higher colon cancer screening rates remains significant and supportive of multiple test providers. We continue to hold our position." View Source
NO
The provided facts do not indicate that Exact Sciences Corporation is launching any new product offerings. While the company is actively developing new products, such as liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, there is no specific mention of new product launches 11121314.
The provided facts do not indicate that Exact Sciences Corporation is launching any new product offerings. While the company is actively developing new products, such as liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, there is no specific mention of new product launches 11121314.
11: Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 2 months ago Exact Sciences Earnings: Guides In Line With Our View; Progress Suggested on Pipeline and Margins Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. Rating Price Target Morningstar• 3 months ago View Source12: Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. View Source13: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. View Source14: Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype Dx, its tissue-based genomic profiling platform with widespread use in breast cancer. It has a promising pipeline in the nascent liquid biopsy market, including a tissue-informed molecular residual disease, or MRD, test, a blood-based CRC screening test, and a multicancer early detection, or MCED, test. View Source
Exact Sciences Corporation's product roadmap for 2024 through 2026 focuses on enhancing its existing cancer screening and diagnostic test portfolio while expanding into new areas of early cancer detection. The company is actively developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. Additionally, Exact Sciences is working on improving the performance characteristics of its flagship Cologuard test and advancing other fluid-based tests. This multipronged approach aims to solidify its leadership in cancer diagnostics and broaden its market presence [fERROR]Exact Sciences Corporation's product roadmap for 2024 through 2026 focuses on enhancing its existing cancer screening and diagnostic test portfolio while expanding into new areas of early cancer detection. The company is actively developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. Additionally, Exact Sciences is working on improving the performance characteristics of its flagship Cologuard test and advancing other fluid-based tests. This multipronged approach aims to solidify its leadership in cancer diagnostics and broaden its market presence [fERROR][fERROR]Exact Sciences Corporation's product roadmap for 2024 through 2026 focuses on enhancing its existing cancer screening and diagnostic test portfolio while expanding into new areas of early cancer detection. The company is actively developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. Additionally, Exact Sciences is working on improving the performance characteristics of its flagship Cologuard test and advancing other fluid-based tests. This multipronged approach aims to solidify its leadership in cancer diagnostics and broaden its market presence [fERROR][fERROR][fERROR]Exact Sciences Corporation's product roadmap for 2024 through 2026 focuses on enhancing its existing cancer screening and diagnostic test portfolio while expanding into new areas of early cancer detection. The company is actively developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. Additionally, Exact Sciences is working on improving the performance characteristics of its flagship Cologuard test and advancing other fluid-based tests. This multipronged approach aims to solidify its leadership in cancer diagnostics and broaden its market presence [fERROR][fERROR][fERROR].